Cancer chemotherapy: alternative routes of drug administration. A review.

This review covers recent developments in regional cancer chemotherapy, including the pharmacological background, technical progress, and clinical experience. Intrathecal chemotherapy is an approach that has acquired an established place, although its ultimate potentials are not known yet. The therapeutic value of hepatic intraarterial drug infusion is still unclear, although this route has been used for more than 20 years. Furthermore, the evaluation of alternative routes via the pleural and peritoneal cavities and other arteries is still in an experimental phase. Interest in these treatment modalities has been stimulated by a number of recent developments in separate fields. Major technical advances have been made, including surgically placed and totally implantable elastic catheters and subcutaneous portals and pumps. In addition, a pharmacokinetic model describing the fate of drugs administered via an artery or cavity has been developed. These developments have made it possible not only to design randomized studies and treat a larger number of patients in a relatively short time with reduced morbidity, but also to improve greatly the selection of drugs, target organs, and administration schedules. Ongoing clinical studies can be expected to lead to improved treatment results as well as provide data on dose-response relationships and drug schedule dependency for specific tumor types.

[1]  S. Howell,et al.  Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Vogelzang Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Handel,et al.  Intracarotid infusion of cis‐diamminedichloroplatinum in the treatment of recurrent malignant brain tumors , 1984, Cancer.

[4]  J M Collins,et al.  Pharmacologic rationale for regional drug delivery. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Torti,et al.  The biology and treatment of superficial bladder cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Issell,et al.  Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa , 1984, Cancer.

[7]  R. Carlson,et al.  Continuous infusion or bolus injection in cancer chemotherapy. , 1983, Annals of internal medicine.

[8]  C. Balch,et al.  A Prospective Phase II Clinical Trial of Continuous FUDR Regional Chemotherapy for Colorectal Metastases to the Liver: Using a Totally Implantable Drug Infusion Pump , 1983, Annals of surgery.

[9]  S. Howell,et al.  Pharmacokinetics of intraarterial mitomycin C in humans. , 1983, Cancer research.

[10]  R. Huben,et al.  Severely contracted bladder following intravesical mitomycin C therapy. , 1983, The Journal of urology.

[11]  F. Freiha,et al.  Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Wallace,et al.  Effective retreatment of patients with colorectal cancer and liver metastases. , 1983, The American journal of medicine.

[13]  A. Gelet,et al.  Lntravesical Instillation of Mitomycin C in the Prophylactic Treatment of Recurring Superficial Transitional Cell Carcinoma of the Bladder , 1983 .

[14]  L M Boxt,et al.  Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  U. Engelmann,et al.  Adriamycin permeability of the rat bladder under different conditions. , 1983, The Journal of urology.

[16]  R. Olshen,et al.  Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. , 1983, Cancer research.

[17]  R. Caprioli,et al.  Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). , 1983, Cancer research.

[18]  J. Jenkins,et al.  Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. , 1983, Cancer research.

[19]  A. Kessinger,et al.  Mini-dose weekly adriamycin therapy for patients with advanced malignant disease at increased risk for adriamycin toxicity. , 1983, American journal of clinical oncology.

[20]  J. Lokich,et al.  The delivery of cancer chemotherapy by constant venous infusion ambulatory management of venous access and portable pump , 1982, Cancer.

[21]  J. Thrall,et al.  Perfusion scintigraphy (Tc-99m MAA) during surgery for placement of chemotherapy catheter in hepatic artery: concise communication. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  R. Olshen,et al.  Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.

[23]  S. Murray,et al.  Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. , 1982, The Journal of clinical investigation.

[24]  R. Ozols,et al.  Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer , 1982, Cancer research.

[25]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[26]  N. Jaffe,et al.  Intraarterial cis‐platinum for patients with inoperable skeletal tumors , 1981, Cancer.

[27]  P. Sugarbaker,et al.  Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. , 1981, Cancer research.

[28]  S. Howell,et al.  Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. , 1981, The Journal of clinical investigation.

[29]  C. Karakousis,et al.  Phase II study—intra‐arterial bcnu therapy for metastatic brain tumors , 1981, Cancer.

[30]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.

[31]  D. Morton,et al.  Is Amputation Necessary for Sarcomas? A Seven‐Year Experience with Limb Salvage , 1980, Annals of surgery.

[32]  R. Dedrick,et al.  Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.

[33]  G. Snow,et al.  External carotid artery infusion with single‐and multiple‐drug regimens in the rat , 1980, Cancer.

[34]  S. Wallace,et al.  Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy , 1980, Cancer.

[35]  V. Devita,et al.  Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. , 1980, Cancer research.

[36]  E. Grady,et al.  Internal radiation therapy of hepatic cancer , 1979, Diseases of the colon and rectum.

[37]  J. Doroshow,et al.  Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. , 1979, Cancer research.

[38]  S. Moss,et al.  Results of a Prospective Ramdomized Study of Hepatic Artery Infusion with 5-Fluorouracil vs. Intravenous 5-Fluorouracil in Patients with Hepatic Metastases from Colo-rectal Cancer , 1979 .

[39]  D. Levin,et al.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. , 1978, Cancer research.

[40]  W. Ensminger,et al.  High‐dose intravenous and hepatic artery infusions of thymidine , 1978, Clinical pharmacology and therapeutics.

[41]  J. Bataini,et al.  Relation between time‐dose and local control of operable breast cancer treated by tumorectomy and radiotherapy or by radical radiotherapy alone , 1978, Cancer.

[42]  D. Byar,et al.  Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. , 1977, Urology.

[43]  Y. Lee Systemic and regional treatment of primary carcinoma of the liver. , 1977, Cancer treatment reviews.

[44]  L. Koss Some ultrastructural aspects of experimental and human carcinoma of the bladder. , 1977, Cancer research.

[45]  M. Soloway Intravesical and systemic chemotherapy of murine bladder cancer. , 1977, Cancer research.

[46]  E. Borden,et al.  Further clinical studies with intrahepatic arterial infusion with 5‐fluorouracil , 1975, Cancer.

[47]  C. Patlak,et al.  Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.

[48]  G. Snow,et al.  Intra-Arterial Infusion with Methotrexate in the Rat , 1974, British Journal of Cancer.

[49]  F. Longo,et al.  Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. , 1969, The Journal of urology.

[50]  C. Nervi,et al.  Protracted Intra Arterial Chemotherapy with Sequential Courses of Antimitotics and Radiotherapy in the Treatment of Extended Head and Neck Cancer , 1968 .

[51]  R. M. Hicks THE FUNCTION OF THE GOLGI COMPLEX IN TRANSITIONAL EPITHELIUM , 1966, The Journal of cell biology.

[52]  E. Watkins,et al.  CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION. , 1964, The New England journal of medicine.

[53]  C. Breedis,et al.  The blood supply of neoplasms in the liver. , 1954, The American journal of pathology.

[54]  H. Bierman,et al.  Hepatic arteriography and the effect of intra-arterial chemotherapeutic agents on met astatic neoplasms of the liver , 1951 .

[55]  T. Winship,et al.  Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. , 1950, Transactions of the ... Meeting of the American Surgical Association. American Surgical Association. Meeting.

[56]  D. Karnofsky,et al.  The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .

[57]  S. Baker,et al.  Intraarterial chemotherapy for head and neck cancer, Part 2: Clinical experience. , 1984, Head & neck surgery.

[58]  F. Schabel,et al.  Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. , 1984, Cancer.

[59]  M. Meyer,et al.  Hepatic arterial streptozocin: a clinical pharmacologic study in patients with liver tumors. , 1983, Cancer drug delivery.

[60]  R. Bryan,et al.  Intraarterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors. , 1983, Cancer drug delivery.

[61]  W. Ensminger,et al.  Regional chemotherapy of neoplastic diseases. , 1983, Pharmacology & therapeutics.

[62]  Y. Rustum,et al.  Inhibition of liver metastases of M 5076 tumor by liposome-entrapped adriamycin. , 1983, Cancer drug delivery.

[63]  J. Burchenal History of intrathecal prophylaxis and therapy of meningeal leukemia. , 1983, Cancer drug delivery.

[64]  S. Woo,et al.  Liposomal methotrexate in the treatment of murine L1210 leukemia. , 1983, Cancer drug delivery.

[65]  T. Landberg,et al.  A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer. , 1982, Clinical therapeutics.

[66]  I. Näslund,et al.  Intravesical instillation with adriamycin + tween 80 in patients with superficial bladder tumors: a preliminary report. , 1982, European urology.

[67]  B. Barlogie,et al.  Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. , 1981, Cancer research.

[68]  R. Hickman,et al.  The Hickman indwelling catheter. , 1980 .

[69]  A. Guarino,et al.  Transport of model compounds across the peritoneal membrane in the rat. , 1978, Pharmacology.

[70]  M. Bagshaw,et al.  A Clinical Study of Chemical Radiosensitization1 , 1969 .